Systematic review and meta‐analysis of bulk RNAseq studies in human Alzheimer’s disease brain tissue

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract We systematically reviewed and meta-analyzed bulk RNA sequencing (RNAseq) studies comparing Alzheimer’s disease (AD) patients to controls in human brain tissue. We searched PubMed, Web of Science, and Scopus for human brain bulk RNAseq studies,...

Parkinsonism in Alzheimer’s disease without Lewy bodies in association with nigral neuron loss: A data‐driven clinicopathologic study

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION Parkinsonism in patients with Alzheimer’s disease (AD) is often attributed to Lewy-related pathology, given its high comorbidity. In the era of anti-amyloid therapy, recognizing parkinsonism caused by AD pathology is needed to optimize the...

Preclinical Alzheimer’s disease shows alterations in circulating neuronal‐derived extracellular vesicle microRNAs in a multiethnic cohort

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION Alzheimer’s disease (AD) is the leading cause of dementia, affecting around 50 million individuals worldwide. Brain-derived extracellular vesicles (EVs) can cross the blood–brain barrier carrying neuron-specific molecules, such as microRNAs...

Chronic stress, social support, and Alzheimer’s blood‐based biomarkers in the HABS‐HD study

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION High levels of chronic stress and low social support have been associated with worse cognition among older adults, but the underlying mechanisms remain unclear. METHODS We included 2117 older adults (mean age 65.5 years) enrolled in the Health...

Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract INTRODUCTION We systematically characterized plasma protein profiles in cerebral amyloid angiopathy (CAA) using proteomics and identified a hub protein panel for disease diagnosis and risk stratification. METHODS A total of 146 patients with probable CAA and...

Predicted natural progression as an Alzheimer’s prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency

by Clinical Neuropsychologist | Wednesday, March 5, 2025 | Dementia

Abstract BACKGROUND Heterogeneity in Alzheimer’s disease (AD) progression introduces variability in treatment effect assessments. Using predicted future progression as an AD prognostic covariate (APC) may reduce this variability. This study evaluates this...